PABLO J CAGNONI
CIK 1205703 · President, Global Head of R&D · last filed 2026-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$26.51M
Companies
7
Total Filings
43
Lifetime Open-Market Net
-$7.20M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INCY | President, Global Head of R&D | 240,848 | $108.53 | $26.14M | -$5.44M | 14 | 2026-06-03 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 5 | 2024-06-04 |
| Rubius Therapeutics, Inc. (RUBY) Delisted | CEO and President | 66,082 | $0.08 | $5.5K | $50.6K | 8 | 2023-02-01 |
| CRSP | Director | 7,500 | $49.80 | $373.5K | -$1.73M | 6 | 2019-11-21 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | — | — | — | $0 | 2 | 2017-06-02 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | EVP, Global R&D and Tech Ops | 16,257 | — | — | $0 | 1 | 2013-03-13 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Sr. VP, Chief Medical Officer | 25,200 | — | — | -$73.3K | 6 | 2009-10-02 |
Recent Filings · Page 3 of 5
43 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-07 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-02 | Rubius Therapeutics, Inc. (RUBY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-30 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-04-15 | Rubius Therapeutics, Inc. (RUBY) Delisted | Buy (P) | +21,000 | $98.7K | EDGAR |
| 2020-02-03 | Rubius Therapeutics, Inc. (RUBY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-11-21 | CRSP | Mixed | — | -$423.1K | EDGAR |
| 2019-11-13 | CRSP | Mixed | — | -$370.6K | EDGAR |
| 2019-11-01 | CRSP | Mixed | — | -$348.1K | EDGAR |
| 2019-06-13 | CRSP | Grant (A) | — | $0 | EDGAR |
| 2019-02-04 | Rubius Therapeutics, Inc. (RUBY) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.